STIFEL FINANCIAL CORP (SF)

US8606301021 - Common Stock

57.71  +0.12 (+0.21%)


Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SF. SF was compared to 200 industry peers in the Capital Markets industry. Both the profitability and financial health of SF have multiple concerns. SF is cheap, but on the other hand it scores bad on growth




Profitability

Profitability Rating

3

The Piotroski-F score of SF is 7.00. This is a strong score and indicates good health and profitability for SF.
SF has a Return On Equity of 11.43%. This is comparable to the industry average of 10.33%.

SF has a Return On Assets of 1.58%. This is below the industry average of 3.76%.
SF's Profit Margin of 12.88% is worse than the rest of the industry. The industry average Profit Margin is 18.20%.
VS Industry

ROA (1.58%) VS Industry: 28% outperformed.

0.06
39.58

ROE (11.43%) VS Industry: 54% outperformed.

0.14
132.26

Profit Margin (12.88%) VS Industry: 32% outperformed.

0.33
140.93

Valuation

Valuation Rating

7

The Price/Earnings Ratio is 10.18, which indicates a very decent valuation of SF.
With a Forward Price/Earnings Ratio of 7.42, the valuation of SF can be described as cheap.
The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
Compared to an average Enterprise Value to EBITDA ratio of 12.56, SF is valued rather cheaply. On top of this, SF has a better ratio than 92% of the companies listed in the same industry.

Compared to an average industry Price/Earning Ratio of 11.05, SF is valued in line with its industry peers.
When comparing the current price to the book value of SF, we can conclude it is valued correctly. It is trading at 1.16 times its book value.
When comparing the price book ratio of SF to the average industry price book ratio of 1.16, SF is valued in line with its industry peers.
VS Industry

Price/Earnings (10.18) VS Industry: 53% outperformed.

564.71
0.11

Price/Book (1.16) VS Industry: 50% outperformed.

96.13
0.06

Enterprise Value/ EBITDA (3.54) VS Industry: 92% outperformed.

168.04
0.47

Growth

Growth Rating

3

Measured over the past 5 years, SF shows a quite strong growth in Earnings Per Share. The EPS has been growing by 16.65% on average per year.
The Earnings Per Share is expected to grow by 6.16% on average over the next 5 years.
SF shows a decrease in Revenue. In the last year, the revenue decreased by -0.66%.
SF shows a small growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 8.92% yearly.

SF is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 4.76% yearly.
SF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.80%.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS16.65% 12.24% -19.8% 20.45% 16.2% 14.59% 6.16%
Revenue8.92% 9.32% -0.66% 5.56% 6.33% 6.96% 4.76%

Health

Health Rating

2

The Debt to Equity ratio of SF is way better than the industry averages.
SF has a good Piotroski-F score of 7.00. This indicates a good health and good profitability for SF.
A Current Ratio of 0.13 indicates that SF may have some problems paying its short term obligations.
When comparing the Current Ratio of SF to the average industry Current Ratio of 1.27, SF is less able to pay its short term obligations than its industry peers. 99% of its industry peers have a better Current Ratio.

A Quick Ratio of 0.13 indicates that SF may have some problems paying its short term obligations.
Compared to an average industry Quick Ratio of 1.26, SF is worse placed to pay its short term obligations than its industry peers. 98% of its industry peers have a better Quick Ratio.
SF has an Altman-Z score of -0.41. This is a bad value and indicates that SF is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 0.80, SF is in worse financial state than most of its industry peers. 94% of its industry peers have a better Altman-Z score.
VS Industry

Debt/Equity (0.22) VS Industry: 62% outperformed.

8.02
0.00

Quick Ratio (0.13) VS Industry: 2% outperformed.

0.03
142.90

Current Ratio (0.13) VS Industry: 1% outperformed.

0.03
142.90

Altman-Z (-0.41) VS Industry: 6% outperformed.

-53.88
113.85

Dividend

Dividend Rating

5

The dividend of SF is nicely growing with an annual growth rate of 48.69%!
SF pays out 29.82% of its income as dividend. This is a sustainable payout ratio.
SF has paid a dividend for at least 10 years, which is a reliable track record.
SF has a Yearly Dividend Yield of 2.51%.

Compared to an average S&P500 Dividend Yield of 2.72, SF has a dividend comparable with the average S&P500 company.
SF's Dividend Yield is slightly below the industry average, which is at 5.44.
SF's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
VS Industry

Dividend Yield (2.51%) VS Industry: 23% outperformed.

0.03
204.17

STIFEL FINANCIAL CORP

NYSE:SF (5/30/2023, 12:35:46 PM)

57.71

+0.12 (+0.21%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)04-26 2023-04-26/bmo
Earnings (Next)07-25 2023-07-25/bmo
Inst Owners83.95%
Inst Owner Change-11.69%
Ins Owners3.18%
Ins Owner Change4%
Market Cap6.16B
Analysts78.57
Price Target72.62 (25.84%)
Dividend
Industry RankSector Rank
Dividend Yield 2.51%
Dividend Growth(5Y)48.69%
DP29.82%
Div Incr Years5
Div Non Decr Years5
Ex-Date05-31 2023-05-31 (0.36)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)-6.32%
Min EPS beat(2)-6.4%
Max EPS beat(2)-6.25%
EPS beat(4)N/A
Avg EPS beat(4)-10.78%
Min EPS beat(4)-16.61%
Max EPS beat(4)-6.25%
Revenue beat(2)2
Avg Revenue beat(2)7.56%
Min Revenue beat(2)5.68%
Max Revenue beat(2)9.44%
Revenue beat(4)2
Avg Revenue beat(4)1.8%
Min Revenue beat(4)-7.29%
Max Revenue beat(4)9.44%
PT rev (1m)-0.56%
PT rev (3m)-7.77%
EPS NQ rev (1m)-4.71%
EPS NQ rev (3m)-10.93%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.16%
Revenue NQ rev (1m)-0.35%
Revenue NQ rev (3m)-2.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.48%
Valuation
Industry RankSector Rank
PE 10.18
Fwd PE 7.42
P/S 1.3
P/FCF 4.56
P/OCF 4.29
P/B 1.16
P/tB 1.61
EV/EBITDA 3.54
EPS(TTM)5.67
EY9.82%
EPS(NY)7.78
Fwd EY13.48%
FCF(TTM)12.65
FCFY21.91%
OCF(TTM)13.44
OCFY23.29%
SpS44.32
BVpS49.93
TBVpS35.75
PEG (NY)0.5
PEG (5Y)0.61
Profitability
Industry RankSector Rank
ROA 1.58%
ROE 11.43%
ROIC 2.57%
ROICexc 2.79%
ROICexgc 3.01%
OM 25.69%
PM 12.88%
GM 98.81%
ROICexgc(3y)2.96%
ROICexcg growth 3Y-5.88%
ROICexcg growth 5Y12.6%
ROICexc(3y)2.7%
ROICexc growth 3Y-4.1%
ROICexc growth 5Y13.25%
OM growth 3Y2.29%
OM growth 5Y15.86%
PM growth 3Y3.52%
PM growth 5Y18.63%
GM growth 3Y0%
GM growth 5Y0.04%
F-Score7
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF 22.67
Debt/EBITDA 23.75
Cap/Depr 116.66%
Profit Quality 221.61%
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z -0.41
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.9%
Cap/Depr(5y)218.22%
Profit Quality(3y)197.42%
Profit Quality(5y)162.12%
Growth
EPS 1Y-19.8%
EPS 3Y12.24%
EPS 5Y16.65%
EPS growth Q2Q-6.04%
EPS Next Y20.45%
EPS Next 2Y16.2%
EPS Next 3Y14.59%
EPS Next 5Y6.16%
Revenue growth 1Y-0.66%
Revenue growth 3Y9.32%
Revenue growth 5Y8.92%
Revenue growth Q2Q12.06%
Revenue Next Year5.56%
Revenue Next 2Y6.33%
Revenue Next 3Y6.96%
Revenue Next 5Y4.76%
EBIT growth 1Y9.71%
EBIT growth 3Y11.82%
EBIT growth 5Y26.19%
EBIT Next Year13.03%
EBIT Next 3Y6.23%
EBIT Next 5Y7.16%
FCF growth 1Y20.94%
FCF growth 3Y31.85%
FCF growth 5Y10.53%
OCF growth 1Y25.02%
OCF growth 3Y22.68%
OCF growth 5Y11.23%
Fundamental Stock Screener Links
Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA